Turning Point Brands (TPB) Q1 2025: White Nicotine Pouch Sales Surge 10x, Forcing Strategic Shift

May 7, 2025 | By EarningsIQ Research

Turning Point Brands delivered a sharp pivot toward modern oral nicotine, with white pouch sales up nearly 10x year-over-year and management raising full-year guidance for the category. Legacy brands remain cash flow engines, but the company is clearly prioritizing investment and market access for its emerging nicotine pouches, even as tariffs and FX headwinds loom. The quarter signals an inflection point in TPB’s business model, with execution in distribution and marketing now critical to capturing long-term share in a rapidly expanding category.

Summary

• Modern Oral Acceleration: White nicotine pouch sales exploded, driving a strategic reallocation of resources.
• Heritage Brands Stability: Legacy products continue to generate strong cash flow, funding new growth bets.
• Guidance Reset: Raised nicotine pouch outlook signals management conviction in category expansion.

Performance Analysis

Turning Point Brands posted 28% revenue growth to $106.4 million, propelled by a step-change in modern oral nicotine sales, which contributed $22.3 million in the quarter. Adjusted EBITDA grew 12% to $27.7 million, with margins pressured by a deliberate shift in mix toward lower-margin but faster-growing nicotine pouches. The Stoker’s segment, now TPB’s largest revenue driver at $59.2 million, saw 63% growth fueled by both chewing tobacco and modern oral, with chewing tobacco volume up as consumers traded down from premium brands. Zig-Zag, the company’s iconic rolling paper and cigar brand, was flat overall, with a 1% revenue increase masking margin pressure from product mix and the unwind of the Clipper relationship.

Gross margin contracted 220 basis points year-over-year to 56%, reflecting the growing weight of modern oral. Management flagged that the change is “mixed-driven,” with higher outbound trade charges and increased sales and marketing investment offsetting some cost savings elsewhere. Free cash flow for the quarter was $12.4 million, with CapEx focused on supporting oral nicotine expansion. Notably, the company maintained strong liquidity with $99.6 million in cash, even as it invests in distribution, headcount, and marketing for its white pouch brands.

• Modern Oral Outpaces Legacy: Modern oral revenue now represents over 20% of total sales, a rapid shift from prior years.
• Margin Pressure from Mix: The pivot to nicotine pouches is diluting gross margins, but management views this as necessary for long-term share capture.
• Cash Flow Engine: Heritage brands continue to fund growth, with Stoker’s chewing tobacco gaining share as consumers trade down.

Q2 will present tough comps for both Zig-Zag and Stoker’s, as the prior year included significant load-in activity and unusually strong segment growth, setting up a test for the durability of recent gains.

Executive Commentary

Strategic Positioning

1. Modern Oral as Growth Engine

TPB is now betting its long-term growth on the modern oral nicotine category, specifically white nicotine pouches (smokeless, spit-free oral nicotine products). Management raised full-year sales guidance for the category by 25%, now targeting $80 to $95 million, and has reallocated sales, marketing, and headcount to accelerate distribution and brand awareness.

2. Route-to-Market Reinvention

The company is refining its go-to-market approach, prioritizing “free” and “out” pouch brands while leveraging joint ventures like TCN for online-first launches. TPB is expanding its sales force, deepening chain account relationships, and investing in omnichannel marketing, including billboard and digital campaigns tied to major retail trials (notably 7-Eleven).

3. Heritage Brands as Cash Flow Base

Stoker’s and Zig-Zag remain foundational, with Stoker’s chewing tobacco gaining share from premium competitors and Zig-Zag maintaining relevance through product innovation (hemp cones) and cultural event marketing. These brands generate the cash to fund the high-growth, high-investment modern oral push.

4. Supply Chain and Onshoring Focus

TPB is exploring U.S. manufacturing for white pouches to both improve profitability and mitigate risks from tariffs and global supply chain volatility. Management sees current supply as sufficient but is actively evaluating domestic production capacity as category scale builds.

5. Regulatory Navigation and PMTA Investment

Ongoing investment in PMTA (Premarket Tobacco Product Application) filings is critical for regulatory approval and long-term category participation. The company expects to spend $3 to $5 million this year supplementing these applications, with timing uncertainty driven by FDA staffing and process changes.

Key Considerations

This quarter marks a clear inflection in TPB’s business model, as management shifts capital and talent toward modern oral nicotine while seeking to preserve the cash flow profile of its heritage portfolio. The scale and speed of this transition will determine TPB’s long-term relevance in a rapidly evolving nicotine market.

Key Considerations:

• Distribution Expansion Pace: Success in landing national chains and scaling online-to-retail transitions will be decisive for modern oral share gains.
• Margin Dilution Risk: The mix shift toward lower-margin pouches will weigh on profitability, at least in the near term, requiring disciplined cost management and eventual price realization.
• Tariff and FX Exposure: Tariffs on imported pouches (estimated $5 to $7 million impact at a 10% rate) and euro strength against the dollar both present ongoing cost headwinds.
• Regulatory Uncertainty: FDA PMTA timing remains opaque, creating a risk overhang for the modern oral category’s long-term growth and market access.

Risks

TPB faces significant execution risk as it pivots to modern oral nicotine, including the challenge of scaling distribution, achieving brand differentiation in a crowded field, and managing the impact of tariffs and regulatory delays. Gross margin pressure from mix shift and potential supply chain disruptions further complicate the outlook, while FDA process uncertainty could delay or limit new product approvals.

Forward Outlook

For Q2 2025, Turning Point Brands guided to:

• Maintain adjusted EBITDA guidance of $108 to $113 million for the full year
• Increase modern oral nicotine sales guidance to $80 to $95 million (from $60 to $80 million)

Management highlighted several factors that will shape near-term results:

• Tough year-over-year comps in Zig-Zag and Stoker’s due to prior-year load-in and segment growth peaks
• Incremental investment in sales, marketing, and PMTA filings to support modern oral expansion

Takeaways

TPB’s Q1 signals a decisive commitment to the modern oral nicotine category, with management raising guidance and ramping investment despite near-term margin headwinds and regulatory risk.

• Modern Oral Inflection: White pouch sales growth and raised guidance confirm the category as TPB’s primary growth lever, demanding flawless execution in distribution and marketing.
• Margin and Regulatory Watch: Investors must monitor ongoing mix-driven margin dilution, tariff impacts, and the opaque PMTA approval timeline as key risk factors.
• Future Focus: The pace of retail rollout, ability to build brand equity, and success in onshoring production will determine whether TPB can convert category momentum into durable market share and profitability.

Conclusion

Turning Point Brands is at a strategic crossroads, with legacy brands underpinning a bold bet on modern oral nicotine. The company’s ability to scale distribution, manage cost pressures, and navigate regulatory complexities will define its trajectory in a rapidly expanding but fiercely competitive market.

Industry Read-Through

TPB’s results highlight the accelerating shift from traditional tobacco to modern oral nicotine, a trend reshaping the entire nicotine landscape. Category growth and brand proliferation signal a land grab phase, with distribution access, regulatory agility, and supply chain localization emerging as key industry battlegrounds. Competitors in tobacco and nicotine must now prioritize omnichannel execution and regulatory investment to remain relevant as consumer preferences evolve and legacy volumes erode. The margin and channel dynamics seen at TPB will likely play out across the sector as the modern oral category matures.

TPB Consumer Staples Tobacco Modern Oral Nicotine Pouches Omnichannel Regulation Tariffs